Last $9.35 USD
Change Today +0.27 / 2.97%
Volume 5.5K
ARDM On Other Exchanges
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

aradigm corp (ARDM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $15.96
52 Week Low
11/5/13 - $6.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARADIGM CORP (ARDM)

Related News

No related news articles were found.

aradigm corp (ARDM) Related Businessweek News

No Related Businessweek News Found

aradigm corp (ARDM) Details

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of respiratory diseases by pulmonologists. The company’s lead development candidates include Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which completed Phase IIb clinical trials for the management of infections associated with the severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its products under development also comprise ARD-1100, a liposomal ciprofloxacin for the treatment of inhalation anthrax and other biodefense purposes; and ARD-1600, an inhaled nicotine product for smoking cessation. The company has a collaboration agreement with Oregon State University. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

12 Employees
Last Reported Date: 05/16/14
Founded in 1991

aradigm corp (ARDM) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $380.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $263.8K
Chief Medical Officer
Total Annual Compensation: $56.8K
Compensation as of Fiscal Year 2013.

aradigm corp (ARDM) Key Developments

Aradigm Corporation Announces Unaudited Consolidated Financial Results for the Second Quarter and Half Year Ended June 30, 2014

Aradigm Corporation announced unaudited consolidated financial results for the second quarter and half year ended June 30, 2014. For the quarter, the company reported revenues of $12,245,000 against $248,000 a year ago. The increase in revenue was due to the recognition of revenue from the Grifols collaboration arrangement as the company is being reimbursed for Pulmaquin(R) project-related costs, as well as the revenue recognized from work being conducted under NIH grants. Loss from operations was $1,347,000 against $2,300,000 a year ago. Net loss was $1,358,000 or $0.09 per basic and diluted share against $2,710,000 or $0.43 per basic and diluted share a year ago. For the half year, the company reported revenues of $18,876,000 against $527,000 a year ago. Loss from operations was $2,169,000 against $5,232,000 a year ago. Net income was $6,397,000 or $0.43 per diluted share against net loss of $6,035,000 or $0.96 per diluted share a year ago.

Aradigm Corporation - Shareholder/Analyst Call

To provide a corporate overview, including an update on the development program for Pulmaquin(R) - Aradigm's proprietary inhaled antibiotic product candidate currently in two Phase 3 clinical trials in non-CF BE patients

Aradigm Corporation - Special Call

To review recent significant milestones, as well as progress with the Pulmaquin program in non-cystic fibrosis bronchiectasis


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDM:US $9.35 USD +0.27

ARDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexza Pharmaceuticals Inc $3.50 USD +0.07
Alkermes PLC $44.73 USD +0.25
Bayer AG €102.05 EUR -0.31
Gilead Sciences Inc $107.56 USD +0.05
GlaxoSmithKline PLC 1,461 GBp -14.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ARDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARADIGM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at